Loading...
New

Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drug, Antidepressant Drugs, Opioids, and Non-Narcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, and Fibromyalgia): Global Opportunity Analysis and Industry Forecast, 2019–2027

A00309
Pages: 216
Aug 2020 | 14195 Views
 
Author(s) : Ankita Sonar, Smita Nerkar , Onkar Sumant
Tables: 100
Charts: 49
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pain Management Drugs Market

Request Now !

The global pain management drugs market was valued at $65,963.1 million in 2019, and is estimated to reach $85,549.3 million by 2027, registering a CAGR of 3.9% from 2020 to 2027.

Pain is a disturbing sensory and emotional sensation that results from tissue damage or disease. In addition, different disorders may cause discomfort, such as multiple sclerosis, osteoarthritis, stomach ulcer, chronic arthritis, fibromyalgia, diabetic neuropathy, and cancer. The length of pain ranges from acute pain for short term to chronic pain for long term. Acute pain can be mild and lasts for only a moment or for weeks, or months. Chronic pain is caused by aged bone & joint conditions, nerve damage, or injury. A variety of drugs is used to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain). Most drugs act by binding to protein targets on cell membranes and affecting biochemical processes of the body.

Pain-Management-Drugs-Market-2020-2027

Get more information on this report : Request Sample Pages

 

Rise in geriatric population is the major factor that drives growth of the global pain management market as aged people are more prone to suffer from joint pain and other chronic conditions. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.

COVID-19 pandemic, which started from Wuhan city of China, has widespread across the globe. This pandemic has disrupted growth in many economies across various domains. The COVID-19 outbreak is expected to impact the pain management drugs market in the initial phase of during the forecast period. The COVID-19 pandemic has stressed healthcare systems worldwide, so many clinics and pain services are no longer open for public services, owing to of safety measures imposed by governments. Subsequently, most chronic pain facilities were deemed non-urgent, both outpatient and elective interventional procedures were limited or stopped during the COVID-19 pandemic to minimize risk of the viral spread. Though the pain management drugs market is expected to register a low down during the forecast period. Furthermore, during the latter half of the forecast period, the demand for pain management drugs is expected to rise, owing to factors such as telemedicine, which has become an appropriate and effective way to offer necessary medical services to patients with chronic pain.

Pain Management Drugs Market
By Drug Class

Your browser does not support the canvas element.

Opioids segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

The global pain management drugs market is segmented on the basis of drug class, indication, and region. On the basis of drug class, the pain management drugs market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and nonnarcotic analgesics. Opioids are further classified into tramadol, hydrocodone, oxycodone, and others (fentanyl, morphine, meperidine, codeine, and methadone). On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Drug class segment review

By drug class, the opioids segment was the largest contributor to the pain management drugs market in 2019, owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

Pain Management Drugs Market
By Indication

Your browser does not support the canvas element.

Neuropathic Pain Segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Indication type segment review

By indication, the neuropathic pain segment accounted for a majority of the pain management drugs market share in 2019, and is expected to exhibit a prominent growth rate during the forecast period, increase in presence of large patient population is the major factor that increases demand for drugs for the segment. Cancer pain and chronic back pain segments are expected to grow at the highest rate throughout the forecast period in 2019, owing to increase in number of surgeries globally and rise in prevalence of chronic diseases that lead to back pain. 

North America accounted for majority of the pain management drugs market share in 2019, and is expected to remain dominant throughout the forecast period. This was attributed to large number of aging population and favorable regulatory conditions. Rise in number of drug abuse cases and addictive nature of opioids has decreased use of prescriptions for opioids in the region, leading to decline in opioid consumption for pain management. On the other side, Asia-Pacific is expected to experience highest growth rate during the forecast period, mainly attributable to presence of larger patient pool and increase in healthcare expenditure in the region.

Some of the key players operating in the pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., Mylan NV., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc. The other prominent players in the value chain include Allergen Inc., Bayer AG, Bristol-Myers Squibb, Valeant Pharmaceuticals International Inc., Boehringer Ingelheim, Sorrento Therapeutics, WEX Pharmaceuticals, and Zynerba Pharmaceuticals.

Pain Management Drugs Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia Pacific region would exhibit the highest CAGR of 4.5% during 2020-2027.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the pain management drugs market growth is provided in the report.
  • The pain management drugs market forecast is studied from 2020 to 2027
  • Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
  • Key market players and their strategies have been analysed to understand the competitive outlook of the market.

Key Market Segments

By Drug Class

  • NSAIDs
  • Anesthetics
  • Anticonvulsants
  • Anti-migraine Agents
  • Antidepressants
  • Opioids 
  • Nonnarcotic Analgesics 

By Indica???????tion

  • Arthritic Pain
  • Neuropathic Pain
  • Cancer Pain
  • Chronic Back Pain
  • Postoperative Pain
  • Migraine
  • Fibromyalgia

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Taiwan
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Government Regulations
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population

3.6.2.Restraints

3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug Exploitation
3.6.2.3.Patent expiration of prescription drugs

3.6.3.Opportunities

3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies

3.7.COVID-19 Impact Analysis for Pain Management Drugs

CHAPTER 4:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDS

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Anticonvulsant

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Antimigraine Drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Antidepressant drugs

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.7.4.Tramadol
4.7.5.Hydrocodone
4.7.6.Oxycodone
4.7.7.Others

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

CHAPTER 5:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic Pain

5.2.1.Market size and forecast, by region
5.2.1.Market analysis, by country

5.3.Neuropathic pain

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Cancer Pain

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Chronic Pain

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Post-operative pain

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Migraine

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Fibromyalgia

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

CHAPTER 6:PAIN MANAGEMENT DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America Pain Management Drugs Market, by country

6.2.2.1.U.S. Pain Management Drugs Market, by drug class
6.2.2.2.U.S Pain Management Drugs Market, by indications
6.2.2.3.Canada Pain Management Drugs Market, by drug class
6.2.2.4.Canada Pain Management Drugs Market, by indication
6.2.2.5.Mexico Pain Management Drugs Market, by product
6.2.2.6.Mexico Pain Management Drugs Market, by indication

6.2.3.North America Pain Management Drugs Market, by drug class
6.2.4.North America Pain Management Drugs Market, by indication

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe Pain Management Drugs Market, by country

6.3.2.1.UK Pain Management Drugs Market, by drug class
6.3.2.2.UK Pain Management Drugs Market, by indication
6.3.2.3.Germany Pain Management Drugs Market, by drug class
6.3.2.4.Germany Pain Management Drugs Market, by indication
6.3.2.5.France Pain Management Drugs Market, by drug class
6.3.2.6.France Pain Management Drugs Market, by indication
6.3.2.7.Italy Pain Management Drugs Market, by drug class
6.3.2.8.Italy Pain Management Drugs Market, by indication
6.3.2.9.Spain Pain Management Drugs Market, by drug class
6.3.2.10.Spain Pain Management Drugs Market, by indication
6.3.2.11.Rest of Europe Pain Management Drugs Market, by drug class
6.3.2.12.Rest of Europe Pain Management Drugs Market, by indication

6.3.3.Europe Pain Management Drugs Market, by drug Class
6.3.4.Europe Pain Management Drugs Market, by indication

6.4.Asia Pacific
6.5.Key market trends, growth factors, and opportunities

6.5.1.Asia-Pacific Pain Management Drugs Market, by country

6.5.1.1.Japan pain management drugs market, by drug class
6.5.1.2.Japan pain management drugs market, by indications
6.5.1.3.China pain management drugs market, by drug class
6.5.1.4.China Pain Management Drugs Market, by indication
6.5.1.5.Australia Pain Management Drugs Market, by drug class
6.5.1.6.Australia Pain Management Drugs Market, by indication
6.5.1.7.India Pain Management Drugs Market, by drug class
6.5.1.8.India Pain Management Drugs Market, by indication
6.5.1.9.South Korea Pain Management Drugs Market, by drug class
6.5.1.10.South Korea Pain Management Drugs Market, by indication
6.5.1.11.Taiwan Pain Management Drugs Market, by drug class
6.5.1.12.Taiwan Pain Management Drugs Market, by indication
6.5.1.13.Rest of Asia-Pacific Pain Management Drugs Market, by drug class
6.5.1.14.Rest of Asia-Pacific Pain Management Drugs Market, by indication

6.5.2.Asia-Pacific Pain Management Drugs Market, by drug Class
6.5.3.Asia-Pacific Pain Management Drugs Market, by indication

6.6.LAMEA

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.LAMEA Pain Management Drugs Market, by country

6.6.2.1.Brazil Pain Management Drugs Market, by drug class
6.6.2.2.Brazil Pain Management Drugs Market, by indication
6.6.2.3.Saudi Arabia Pain Management Drugs Market, by drug class
6.6.2.4.Saudi Arabia Pain Management Drugs Market, by indication
6.6.2.5.South Africa Pain Management Drugs Market, by drug class
6.6.2.6.South Africa Pain Management Drugs Market, by indication
6.6.2.7.Rest of LAMEA Pain Management Drugs Market, by drug class
6.6.2.8.Rest of LAMEA Pain Management Drugs Market, by indication

6.6.3.LAMEA Pain Management Drugs Market, by drug Class
6.6.4.LAMEA Pain Management Drugs Market, by indication

CHAPTER 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.ELI LILY AND COMPANY

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.

7.4.GLAXOSMITHKLINE PLC (GSK)

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments

7.5.JOHNSON & JOHNSON

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.MERCK & CO., INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.MYLAN N.V.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments

7.8.NOVARTIS INTERNATIONAL AG

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.PFIZER INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.PURDUE PHARMA L.P.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 11.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 12.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 13.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019–2027 ($MILLION)
TABLE 16.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 21.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 22.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 23.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 24.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 26.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 27.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 29.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019–2027 ($MILLION)
TABLE 30.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 31.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 33.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 34.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 35.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 36.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 37.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 39.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 40.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 41.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 42.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 43.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 44.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 45.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 46.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 48.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 49.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 50.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 51.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 52.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 54.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 55.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 56.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 61.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 62.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 63.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 64.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 65.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 67.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 68.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 69.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.ABBOTT: COMPANY SNAPSHOT
TABLE 71.ABBOTT: OERATING SEGMENT
TABLE 72.ABBOTT: PRODUCT PORTFOLIO
TABLE 73.ELI LILLY: COMPANY SNAPSHOT
TABLE 74.LILLY: OPERATING SEGMENTS
TABLE 75.ELI LILLY: PRODUCT PORTFOLIO
TABLE 76.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 77.ENDO: COMPANY SNAPSHOT
TABLE 78.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 79.ENDO: PRODUCT PORTFOLIO
TABLE 80.GSK: COMPANY SNAPSHOT
TABLE 81.GSK: OPERATING SEGMENTS
TABLE 82.GSK: PRODUCT PORTFOLIO
TABLE 83.J&J: COMPANY SNAPSHOT
TABLE 84.J&J: OPERATING BUSINESS SEGMENTS
TABLE 85.J&J: PRODUCT PORTFOLIO
TABLE 86.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 87.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 88.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 89.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90.MYLAN: COMPANY SNAPSHOT
TABLE 91.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 92.MYLAN: PRODUCT PORTFOLIO
TABLE 93.NOVARTIS: COMPANY SNAPSHOT
TABLE 94.NOVARTIS: OPERATING SEGMENTS
TABLE 95.NOVARTIS: PRODUCT PORTFOLIO
TABLE 96.PFIZER: COMPANY SNAPSHOT
TABLE 97.PFIZER: OERATING SEGMENT
TABLE 98.PFIZER: PRODUCT PORTFOLIO
TABLE 99.PURDUE: COMPANY SNAPSHOT
TABLE 100.PURDUE: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 05.TOP PLAYER POSTIONING, 2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
FIGURE 11.DRIVER, RESTRAINSTS AND OPPORTUNITIES
FIGURE 12.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANESTHETIC BY COUNTRY,  2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANT BY COUNTRY,  2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIMIGRAINE BY COUNTRY,  2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANT DRUGS BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS  BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHMITIC PAIN BY COUNTRY,  2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY,  2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY,  2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN BY COUNTRY,  2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINEBY COUNTRY,  2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY COUNTRY,  2019 & 2027 (%)
FIGURE 26.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 31.ENDO: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.ENDO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 33.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 47.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 49.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)

 
 

The demand for pain management drugs has increased rapidly over recent years. Pain can be caused due to various reasons such as chronic diseases, cancer, and surgeries. Thus, these segments are the largest contributors to the market growth. Presence of large geriatric population base, rise in global prevalence of cancer, and availability of pipeline drugs that pose to be promising treatment options for patients with chronic diseases contribute to growth of the market. 

However, patent expiration of major best-seller drugs such as pregabalin and duloxetine by Pfizer and Eli Lilly & Co., respectively, and availability of alternative therapies such as acupuncture, massage, and medical devices hamper the market growth.

Employment of pain management drugs is the highest in North America, owing to increase in adoption of these drugs, high prevalence of chronic diseases, and increase in disposable income of customers. In addition, presence of a large geriatric population and favorable regulatory & healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010 supplement the market growth. 

Although the use of pain management drugs in Asia-Pacific and LAMEA is low, the adoption rate is expected to increase, owing to rise in disposable income and surge in incidences of chronic diseases. China and India are potential markets in Asia-Pacific. Moreover, increase in R&D investments, upsurge in healthcare expenditure, and rise in government funding & initiatives propel the market growth in Asia-Pacific.
 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The total market value of pain management drugs market is $65,963.1 million in 2019.

A. The forcast period for pain management drugs market is 2020 to 2027

A. The market value of pain management drugs market in 2020 is $65,528.4 million.

A. The base year is 2019 in pain management drugs market

A. Top companies such as, Pfizer, Mylan, Johnson & Johnson, Eli Lily & company, Merck & Co, Inc, and Abbott Laborateries held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in all region

A. Opioids segment is the most influencing segment owing to high efficiency of opioids to relieve pain in major chronic conditions. The anesthetics segment is anticipated to possess highest growth rate during the forecast period.

A. The major factor that fuels the growth of the pain management drugs market includes surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market.

A. This drugs are often prescribed for acute pain that arises from traumatic injury, such as surgery , neuropathic pain.

A. Pain is a distressing sensory and emotional sensation, which is caused by tissue injury or disease. Pain management involves reducing or treating pain by using a given range of medications. There are several medicines available, which provide pain relief through a variety of physiological mechanisms such as targeting nociceptors.

A. Opioids and Post-operative Pain segment is the key matured markets growing in the pain management drug market.

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Pain Management Drugs Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts